SeqLL Announces Fourth Quarter and Year End 2022 Financial Results
BILLERICA, Mass., March 17, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company...
BILLERICA, Mass., March 17, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company...
NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
SEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for...
Company to provide a detailed overview of its norovirus clinical program Webcast to be held on March 28, 2023 at...
Fort Lee, NJ, March 17, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage...
Enrollment Underway in Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March...
Net sales for the fourth quarter of 2022 were $12.2 million, down 7.4% compared to $13.2 million for the fourth...
Patient feedback from the standardized Brief Addiction Monitor (BAM) assessment demonstrates reductions in drug and alcohol usage, and other risk...
Internationally Recognized Academic Leader Awarded the National Institute for Health Research (NIHR) Research Rising Star Award, and Cardiovascular and Interventional...
Award recognizes NeuroStar for its significant contributions toward patient wellbeingMALVERN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:...
Remi now cleared for use with most commonly used 2D and 3D imaging systems for spine surgeryPALM BEACH GARDENS, Fla.,...
Growing body of data supports Ampligen’s potential as both a prophylactic and an early-onset therapy against human Ebola virus disease...
New research released at ACMG Annual Clinical Genetics Meeting reiterates the superiority of exome sequencing’s role in shortening the diagnostic...
– CD20-targeted GADLEN demonstrated preclinical proof of concept of rapid B cell depletion in humanized mice and non-human primates, intended for...
Subjects completed 16-week treatment with no significant safety issues Topline results expected in the first half of 2023 SCOTTSDALE, Ariz.,...
DEERFIELD, Ill., March 16, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on...
MINNEAPOLIS, March 16, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and...
DURHAM, N.C., March 16, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in...
Company plans to initiate phase I/IIa in-human clinical trials in Q2 2023 Tel Aviv, Israel / Vancouver, Canada, March 16,...
Pharmanovia to acquire license to GHRYVELIN™from Aeterna Zentaris’ existing licensee, Consilient Health, effective immediatelyTORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE)...